The Global Alzheimer's Platform Foundation® (GAP) is pleased to welcome Spear Bio, a biotechnology company pioneering wash-free ultrasensitive immunoassay technology, to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images as well as numerous races and ethnicities to generate data that may help predict, detect and diagnose Alzheimer's disease and related dementias. The Bio-Hermes-002 study collects data reflecting the performance of each biomarker in the study, or combination of biomarkers, to assess, diagnose or predict the presence of a variety of pathologies associated with Alzheimer's Disease and related dementias including amyloid and tau in the brain – hallmark characteristics of Alzheimer's disease. In Bio-Hermes-002, Spear Bio will provide results of blood-based biomarker analysis using its SPEAR UltraDetect™ assay platform that offers attomolar sensitivity from 1 uL diluted sample and superior specificity of homogenous wash-free format in an effort to change the paradigm of early-stage disease diagnostics and monitoring for Bio-Hermes-002, building upon findings from Bio-Hermes-001. We're proud to have Spear Bio as a valued partner in the Bio-Hermes-002 study. Their technology platform is consistent with our goal to catalyze and scale early-stage disease diagnostics and monitoring, therby transforming how we treat patients and conduct clinical trials for Alzheimer's and related dementias. By advancing biomarker detection, we hope to accelerate meaningful progress for individuals and families affected by these conditions.” The AD Workbench is a global, secure, cloud-based data sharing and analytics environment that enables researchers worldwide to share, access, and analyze data across multiple platforms. Spear Bio joins a list of industry leaders who are partners in this study, including Biogen and Eli Lilly and Company, IXICO, and Roche along with a growing list of exceptional partners providing blood-based biomarker assessments or digital assessments for Bio-Hermes-002. To date, the partners include AINOSTICS, Alamar Biosciences , Beckman Coulter Diagnostics, Cambridge Cognition Limited, Cognivue, Cumulus Neuroscience Limited, Fujirebio, iLoF, LifeArc, Linus Health, Lucent Diagnostics–a Quanterix brand, Sunbird Bio, and ViewMind. Please use one of the following formats to cite this article in your essay, paper or report: Global Alzheimer's Platform Foundation announces strategic collaboration and partnership with Spear Bio for the transformative Bio-Hermes-002 study. "Global Alzheimer's Platform Foundation announces strategic collaboration and partnership with Spear Bio for the transformative Bio-Hermes-002 study". "Global Alzheimer's Platform Foundation announces strategic collaboration and partnership with Spear Bio for the transformative Bio-Hermes-002 study". Global Alzheimer's Platform Foundation announces strategic collaboration and partnership with Spear Bio for the transformative Bio-Hermes-002 study. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. To start a conversation, please log into your AZoProfile account first, or create a new account. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. Please read and accept to continue. Please check the box above to proceed. Azthena may occasionally provide inaccurate responses. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.